The pulmonary route is an interesting route for drug administration, both for effective local
therapy (asthma, chronic obstructive pulmonary disease or cystic fibrosis) and for the …

In the last decades, dry powder inhalation has become a very attractive option for pulmonary
drug delivery to treat lung diseases like cystic fibroses and lung infections. In contrast to the …

This review examines the key issues surrounding the development and preparation of
formulations for dry powder inhalers. The various inhaler devices that are currently available …

Dry powder inhalers (DPIs) are a widely accepted inhaled delivery dosage form, particularly
in Europe, where they currently are used by a large number of patients for the delivery of …

Dry powder inhalers (DPIs) have been available for delivering drugs to the lungs for over 30
years. In the last decade there has been a big increase in DPI development, resulting partly …

Enhanced therapeutics are drug products derived from existing generic drugs that provide
additional benefits to the patients and the healthcare system. Enhanced therapeutics are …

Pulmonary drug delivery is currently the focus of accelerated research and development
because of the potential to produce maximum therapeutic benefit to patients by directly …

Pulmonary drug delivery is the focus of much research and development because of its
great potential to produce maximum therapeutic benefit. Among the available options the dry …

Dry powder inhalers (DPIs) are an important and increasingly investigated method of
modern therapy for a growing number of respiratory diseases. DPIs are a promising option …

The inhalation of aerosolised drug has become a well established treatment modality in
conditions such as asthma. The pressurised metered-dose inhaler (MDI) is still the most …